China’s SciNeuro, Novartis sign US$1.7 billion licensing deal to develop Alzheimer’s drugs

    China’s SciNeuro, Novartis sign US$1.7 billion licensing deal to develop Alzheimer’s drugs

    A partnership between China’s SciNeuro Pharmaceuticals and Swiss pharmaceutical giant Novartis on Monday has revived hopes for treating Alzheimer’s disease. The deal, worth nearly US$1.7 billion, grants Novartis exclusive worldwide rights to develop and commercialise SciNeuro’s antibody candidates to develop drugs for the progressive brain disease. SciNeuro’s novel amyloid beta targeted antibody programme leverages proprietary…

    Read More
    Swiss drugmaker Novartis says it can withstand potential tariffs; TikTok deal reached as US and China seek to break trade deadlock

    Swiss drugmaker Novartis says it can withstand potential tariffs; TikTok deal reached as US and China seek to break trade deadlock

    The CEO of Swiss pharmaceutical company Novartis said Saturday that it has enough stockpiles in the US to withstand any potential tariffs from President Trump, Reuters reported. Pharmaceuticals are exempt from the 39% tariffs Trump slapped on Switzerland in August, but an EU trade deal reached in July includes a 15% tariff on most drugs,…

    Read More